Fig. 1. Patient characteristics at baseline and individual disease trajectories.
a, Baseline characteristics of eight patients with progressive DMG H3K27M+ before initiation of treatment with H3K27M-vac. Age specified in years, tumor size measured as product of maximal orthogonal diameter on contrast-enhanced T1-weighted MRI sequences (mm2); cumulative dose of intensity-modulated radiotherapy measured in Gy; TMZ, temozolomide (75 mg m−2 body surface area (BSA)) daily during radiotherapy; CCNU, lomustine (110 mg m−2 BSA d1, TMZ mg m−2 BSA d2–6, q42d for six cycles); oral dexamethasone intake in mg d−1. Brain illustration taken from Adobe Stock Standard under License ID 222738500. b, Swimmer plot depicting clinical course since initial diagnosis, vaccine administration and time point of first H3K27M-specific immune responses in peripheral blood (n = 8 patients).